US 20210332110A1

(19) United States

(12) Patent Application Publication

Nussenzweig et al.

(10) Pub. No.: US 2021/0332110 A1

(43) Pub. Date: Oct. 28, 2021

(54) **NEUTRALIZING ANTI-SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF**

(71) Applicant: **The Rockefeller University**, New York, NY (US)

(72) Inventors: **Michel Nussenzweig**, New York, NY (US); **Davide F. Robbiani**, New York, NY (US)

(73) Assignee: **The Rockefeller University**, New York, NY (US)

(21) Appl. No.: **17/242,583**

(22) Filed: **Apr. 28, 2021**

Related U.S. Application Data

(60) Provisional application No. 63/119,088, filed on Nov. 30, 2020, provisional application No. 63/038,384, filed on Jun. 12, 2020, provisional application No. 63/032,112, filed on May 29, 2020, provisional application No. 63/021,387, filed on May 7, 2020, provisional application No. 63/016,569, filed on Apr. 28, 2020.

Publication Classification

(51) **Int. Cl.**

C07K 16/10	(2006.01)
A61K 45/06	(2006.01)
G01N 33/569	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/10*** (2013.01); ***A61K 45/06*** (2013.01); ***G01N 33/56983*** (2013.01); *C07K 2317/565* (2013.01); *C07K 2317/35* (2013.01); *C07K 2317/33* (2013.01); *C07K 2317/31* (2013.01); *G01N 2333/165* (2013.01); *C07K 2317/76* (2013.01)

(57) **ABSTRACT**

This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.

Specification includes a Sequence Listing.